(Q36376401)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Cost-effectiveness of moderate-to-severe psoriasis treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

16 January 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Drew W Miller

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

157-167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16433581%20AND%20SRC:MED&resulttype=core&format=json

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Psoriasis--epidemiology and clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

The annual cost of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

The economic impact of psoriasis increases with psoriasis severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Therapeutic strategies for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Cutaneous squamous-cell carcinoma in patients treated with PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Diagnosis and treatment of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Duration of remission of psoriasis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

AAD consensus statement on psoriasis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Biological therapies in the systemic management of psoriasis: International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157

Phototherapy utilization for psoriasis is declining in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.157